ClinicalTrials.gg
Active, not recruitingNCT04033445QUASARUpdated Nov 4, 2026Results posted

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3 interventional study of Placebo and Guselkumab in Ulcerative Colitis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 392 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,064
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
3rd of 28
1,064 · median 205
Started
2019
the only one that year
Phase 2/3
3 of 43
none open now
Primary completion
2023-09
later than 0 of 20 live
Registered
22nd of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 2/3, reaches primary completion later than 0 of the 20 other live ones, and was the 22nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of ulcerative colitis (UC)
  • Moderately to severely active UC, defined by modified Mayo score
  • Demonstrated inadequate response or intolerance to medical therapies specified in the protocol
  • Screening laboratory test results within the parameters specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease
  • UC limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon
  • Presence of a stoma
  • Presence or history of a fistula
  • Receiving prohibited medications and/or treatment
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,064 participants (actual)

Study arms

  • Experimental
    Induction Study 1: Guselkumab Dose 1

    Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.

    Drug: Guselkumab

  • Experimental
    Induction Study 1: Guselkumab Dose 2

    Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.

    Drug: Guselkumab

  • Placebo comparator
    Induction Study 1: Placebo IV

    Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.

    Drug: Placebo

  • Experimental
    Induction Study 2: Guselkumab IV

    Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.

    Drug: Guselkumab

  • Placebo comparator
    Induction Study 2: Placebo IV

    Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.

    Drug: Placebo

  • Experimental
    Maintenance Study: Maintenance Dose Regimen 1

    Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).

    Drug: Guselkumab

  • Experimental
    Maintenance Study: Maintenance Dose Regimen 2

    Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).

    Drug: Guselkumab

  • Placebo comparator
    Maintenance Study: Placebo SC

    Participants will receive matching placebo SC q4w.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Participants will receive matching placebo IV or SC.

  • Participants will receive guselkumab IV or SC.

06

What researchers measure

Primary outcomes

  1. Induction Study 1: Percentage of Participants With Clinical Response at Week I-12

    Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.

    Time frame: At Week I-12

  2. Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12

    Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.

    Time frame: At Week I-12

  3. Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44

    Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-1 and IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for randomized arms only.

    Time frame: At Week M-44

Secondary outcomes

  1. Induction Study 1: Percentage of Participants With Clinical Remission at Week I-12

    Time frame: At Week I-12

  2. Induction Study 1: Percentage of Participants With Symptomatic Remission at Week I-12

    Time frame: At Week I-12

  3. Induction Study 1: Percentage of Participants With Endoscopic Healing at Week I-12

    Time frame: At Week I-12

  4. Induction Study 1: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12

    Time frame: At Week I-12

  5. Induction Study 1: Percentage of Participants With Endoscopic Normalization at Week I-12

    Time frame: At Week I-12

  6. Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-12

    Time frame: At Week I-12

  7. Induction Study 2: Percentage of Participants With Endoscopic Healing at Week I-12

    Time frame: At Week I-12

  8. Induction Study 2: Percentage of Participants With Clinical Response at Week I-12

    Time frame: At Week I-12

  9. Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-4

    Time frame: At Week I-4

  10. Induction Study 2: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week I-12

    Time frame: At Week I-12

  11. Induction Study 2: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12

    Time frame: At Week I-12

  12. Induction Study 2: Percentage of Participants With Fatigue Response at Week I-12

    Time frame: At Week I-12

  13. Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-2

    Time frame: At Week I-2

  14. Induction Study 2: Percentage of Participants With Endoscopic Normalization at Week I-12

    Time frame: At Week I-12

  15. Maintenance Study: Percentage of Participants With Symptomatic Remission at Week M-44

    Time frame: At Week M-44

  16. Maintenance Study: Percentage of Participants With Endoscopic Healing at Week M-44

    Time frame: At Week M-44

  17. Maintenance Study: Percentage of Participants With Corticosteroid-free Clinical Remission at Week M-44

    Time frame: At Week M-44

  18. Maintenance Study: Percentage of Participants With Clinical Response at Week M-44

    Time frame: At Week M-44

  19. Maintenance Study: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week M-44

    Time frame: At Week M-44

  20. Maintenance Study: Percentage of Participants With IBDQ Remission at Week M-44

    Time frame: At Week M-44

  21. Maintenance Study: Percentage of Participants With Fatigue Response at Week M-44

    Time frame: At Week M-44

  22. Maintenance Study: Percentage of Participants With Clinical Remission at Week 44 Among the Participants Who Had Achieved Clinical Remission at Maintenance Baseline

    Time frame: At Week M-44

  23. Maintenance Study: Percentage of Participants With Endoscopic Normalization at Week M-44

    Time frame: At Week M-44

07

Results

Posted Nov 18, 2024

Participant flow

This study consisted of 3 separate studies: induction study 1 (IS-1), induction study 2 (IS-2) and maintenance study (MS). In IS-1 and IS-2, participants with modified Mayo score (MMS) of 4 to 9 at baseline (Induction Week 0 \[Week I-0\]) with inadequate response or failed to tolerate conventional or advanced therapy were enrolled.

IS-1 and IS-2 Period 1 (Week 0 to 12)
Participant flow — IS-1 and IS-2 Period 1 (Week 0 to 12)
MilestoneIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20MS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4wMS: Nonrandomized: Placebo SC q4wMS: Nonrandomized: Guselkumab 200 mg SC q4w
Started109108111002964400000000
Treated108108111002954400000000
Full analysis set (fas)105101107002804210000000
Fas participants who enrolled into ms32606500822740000000
Completed103105110002704220000000
Not completed6310026180000000
Withdrew: Adverse event21000970000000
Withdrew: Death00000110000000
Withdrew: Lack of efficacy20000020000000
Withdrew: Physician decision00000210000000
Withdrew: Pregnancy00000010000000
Withdrew: Withdrawal by subject111001260000000
Withdrew: Other01000100000000
Withdrew: Randomized but not treated10000100000000
IS-1 and IS-2 Period 2 (Week 12 to 24)
Participant flow — IS-1 and IS-2 Period 2 (Week 12 to 24)
MilestoneIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20MS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4wMS: Nonrandomized: Placebo SC q4wMS: Nonrandomized: Guselkumab 200 mg SC q4w
Started00067790017212900000
Is-1: period 1 guselkumab 200 mg iv non responders000038000000000
Is-1: period 1 guselkumab 400 mg iv non responders000041000000000
Treated00067790017112900000
Fas participants who enrolled into ms0004949001207400000
Completed00064770016211700000
Not completed0003200101200000
Withdrew: Adverse event00022004600000
Withdrew: Lack of efficacy00000001300000
Withdrew: Lost to follow-up00000000100000
Withdrew: Protocol violation00010000000000
Withdrew: Withdrawal by subject00000003200000
Withdrew: Other00000001000000
Withdrew: Crossed over but not treated00000001000000
Maintenance Study (Week 0 to Week 44)
Participant flow — Maintenance Study (Week 0 to Week 44)
MilestoneIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20MS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4wMS: Nonrandomized: Placebo SC q4wMS: Nonrandomized: Guselkumab 200 mg SC q4w
Started000000000201199199122125
Treated000000000201199199122125
Full analysis set000000000190188190114123
Safety all randomized and treated analysis set00000000020319719900
Dose adjustment00000000075233100
Safety all nonrandomized and treated analysis set000000000000122125
Completed00000000017317717695107
Not completed0000000002822232718
Withdrew: Adverse event00000000012910115
Withdrew: Lack of efficacy00000000063153
Withdrew: Lost to follow-up00000000001101
Withdrew: Physician decision00000000004121
Withdrew: Withdrawal by subject00000000084765
Withdrew: Non-compliance with study drug00000000000001
Withdrew: Other00000000011222
Withdrew: Site closure in ukraine00000000010110

Outcome measures

PrimaryInduction Study 1: Percentage of Participants With Clinical Response at Week I-12

Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.

Time frame:
At Week I-12
Reported as:
Number · Percentage of participants
Induction Study 1: Percentage of Participants With Clinical Response at Week I-12
Percentage of participantsIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8
Induction Study 1: Percentage of Participants With Clinical Response at Week I-1227.661.460.7
Statistical analysis
  • IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 vs IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 · Cochran-Mantel-Haenszel (CMH) chi-square · p = < 0.001 · Adjusted treatment difference: 33.6 · 95% CI 20.9 to 46.3Treatment difference between guselkumab group and placebo group was adjusted with CMH weight.
  • IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 vs IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 · CMH chi-square test · p = < 0.001 · Adjusted treatment difference: 33.1 · 95% CI 20.8 to 45.4Treatment difference between guselkumab group and placebo group was adjusted with CMH weight.
PrimaryInduction Study 2: Percentage of Participants With Clinical Remission at Week I-12

Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.

Time frame:
At Week I-12
Reported as:
Number · Percentage of participants
Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12
Percentage of participantsIS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8
Induction Study 2: Percentage of Participants With Clinical Remission at Week I-127.9 (4.7 to 11.0)22.6 (18.6 to 26.6)
Statistical analysis
  • IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 vs IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 · CMH chi-square test · p = < 0.001 · Adjusted treatment difference: 14.9 · 95% CI 9.9 to 19.9Treatment difference between guselkumab group and placebo group was adjusted with CMH weight.
PrimaryMaintenance Study: Percentage of Participants With Clinical Remission at Week M-44

Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-1 and IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for randomized arms only.

Time frame:
At Week M-44
Reported as:
Number · Percentage of participants
Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44
Percentage of participantsMS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4w
Maintenance Study: Percentage of Participants With Clinical Remission at Week M-4418.9 (13.4 to 24.5)45.2 (38.1 to 52.3)50.0 (42.9 to 57.1)
Statistical analysis
  • MS: Randomized: Placebo SC Every 4 Weeks (q4w) vs MS: Randomized: Guselkumab 100 mg SC q8w · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted treatment difference: 25.2 · 95% CI 16.4 to 33.9Treatment difference between guselkumab group and placebo group was adjusted with CMH weight.
  • MS: Randomized: Placebo SC Every 4 Weeks (q4w) vs MS: Randomized: Guselkumab 200 mg SC q4w · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted treatment difference: 29.5 · 95% CI 20.9 to 38.1Treatment difference between guselkumab group and placebo group was adjusted with CMH weight.
SecondaryInduction Study 1: Percentage of Participants With Clinical Remission at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 1: Percentage of Participants With Symptomatic Remission at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 1: Percentage of Participants With Endoscopic Healing at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 1: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 1: Percentage of Participants With Endoscopic Normalization at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Symptomatic Remission at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Endoscopic Healing at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Clinical Response at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Symptomatic Remission at Week I-4
Time frame:
At Week I-4

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Fatigue Response at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Symptomatic Remission at Week I-2
Time frame:
At Week I-2

Results for this outcome have not been posted.

SecondaryInduction Study 2: Percentage of Participants With Endoscopic Normalization at Week I-12
Time frame:
At Week I-12

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Symptomatic Remission at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Endoscopic Healing at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Corticosteroid-free Clinical Remission at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Clinical Response at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With IBDQ Remission at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Fatigue Response at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Clinical Remission at Week 44 Among the Participants Who Had Achieved Clinical Remission at Maintenance Baseline
Time frame:
At Week M-44

Results for this outcome have not been posted.

SecondaryMaintenance Study: Percentage of Participants With Endoscopic Normalization at Week M-44
Time frame:
At Week M-44

Results for this outcome have not been posted.

Adverse events

Collected over IS-1 and 2 Period 1: From Week I-0 to Week I-12; IS-1 and 2 Period 2: From Week I-12 to 12 weeks after last dose of study drug (up to 32 weeks); MS: from Week M-0 up to Week M-44. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-80/109 (0%)7/108 (6.5%)49/108 (45.4%)
IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-80/108 (0%)1/108 (0.9%)33/108 (30.6%)
IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-80/111 (0%)3/111 (2.7%)38/111 (34.2%)
IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-200/67 (0%)2/67 (3%)17/67 (25.4%)
IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-200/79 (0%)3/79 (3.8%)15/79 (19%)
IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-82/296 (0.7%)21/295 (7.1%)88/295 (29.8%)
IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-81/440 (0.2%)13/440 (3%)118/440 (26.8%)
IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-200/172 (0%)4/171 (2.3%)38/171 (22.2%)
IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-200/129 (0%)3/129 (2.3%)37/129 (28.7%)
MS: Randomized: Placebo SC Every 4 Weeks (q4w)0/203 (0%)3/203 (1.5%)112/203 (55.2%)
MS: Randomized: Guselkumab 100 mg SC q8w0/197 (0%)5/197 (2.5%)93/197 (47.2%)
MS: Randomized: Guselkumab 200 mg SC q4w0/199 (0%)12/199 (6%)109/199 (54.8%)
MS: Nonrandomized: Placebo SC q4w0/122 (0%)13/122 (10.7%)69/122 (56.6%)
MS: Nonrandomized: Guselkumab 200 mg SC q4w0/125 (0%)7/125 (5.6%)76/125 (60.8%)
MS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4w0/75 (0%)2/75 (2.7%)28/75 (37.3%)
MS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4w0/23 (0%)1/23 (4.3%)14/23 (60.9%)
MS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w0/31 (0%)2/31 (6.5%)20/31 (64.5%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20MS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4wMS: Nonrandomized: Placebo SC q4wMS: Nonrandomized: Guselkumab 200 mg SC q4wMS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4wMS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4wMS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w
Colitis UlcerativeGastrointestinal disorders4/1080/1081/1111/672/7915/2956/4401/1711/1291/2031/1971/1992/1222/1251/750/231/31
Anal FistulaGastrointestinal disorders0/1080/1080/1110/670/790/2950/4400/1710/1290/2030/1970/1991/1220/1250/751/230/31
Anal AbscessInfections and infestations0/1080/1080/1110/670/790/2950/4400/1710/1290/2030/1970/1991/1220/1250/751/230/31
Adenovirus InfectionInfections and infestations0/1080/1080/1110/670/790/2950/4400/1710/1290/2030/1970/1990/1220/1250/750/231/31
Herpes ZosterInfections and infestations0/1080/1080/1111/670/790/2950/4400/1710/1290/2030/1970/1990/1220/1250/750/230/31
AnaemiaBlood and lymphatic system disorders0/1081/1081/1110/671/791/2951/4400/1710/1290/2030/1970/1990/1220/1251/750/230/31
Acute AbdomenGastrointestinal disorders0/1080/1080/1110/671/790/2950/4400/1710/1290/2030/1970/1990/1220/1250/750/230/31
PyrexiaGeneral disorders0/1080/1080/1110/671/790/2950/4400/1710/1290/2030/1970/1990/1220/1250/750/230/31
Covid-19Infections and infestations0/1080/1080/1110/671/790/2950/4401/1710/1290/2030/1970/1991/1220/1250/750/230/31
HypoproteinaemiaMetabolism and nutrition disorders0/1080/1080/1110/671/790/2950/4400/1710/1290/2030/1970/1990/1220/1250/750/230/31
Most frequent other events
Showing 10 of 55
Most frequent other events
EventIS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20MS: Randomized: Placebo SC Every 4 Weeks (q4w)MS: Randomized: Guselkumab 100 mg SC q8wMS: Randomized: Guselkumab 200 mg SC q4wMS: Nonrandomized: Placebo SC q4wMS: Nonrandomized: Guselkumab 200 mg SC q4wMS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4wMS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4wMS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w
Colitis UlcerativeGastrointestinal disorders3/1081/1083/1112/673/7912/2955/4407/1717/12959/20320/19726/19926/12221/1257/752/235/31
Covid-19Infections and infestations5/1086/1082/1111/671/7913/29522/44013/1719/12928/20328/19720/19919/12223/1255/753/232/31
AnaemiaBlood and lymphatic system disorders11/1088/1089/1114/672/7920/29522/4404/1716/1295/2035/1976/1995/1226/1253/752/230/31
HaemorrhoidsGastrointestinal disorders1/1080/1082/1110/670/791/2954/4401/1711/1291/2031/1970/1993/1222/1250/752/231/31
TonsillitisInfections and infestations1/1080/1080/1110/670/790/2951/4400/1710/1292/2033/1972/1990/1225/1250/752/230/31
HeadacheNervous system disorders8/1083/1086/1112/673/798/29513/4401/1710/12912/2038/1979/1998/1225/1253/752/230/31
ArthralgiaMusculoskeletal and connective tissue disorders3/1082/1084/1111/671/796/2957/4402/1712/12913/20312/19716/1995/1225/1251/751/231/31
Upper Respiratory Tract InfectionInfections and infestations0/1081/1081/1113/670/791/2955/4402/1711/1298/2036/19715/1992/1225/1252/750/231/31
NasopharyngitisInfections and infestations2/1080/1081/1110/670/798/2956/4405/1713/12910/2038/1977/1999/1227/1253/750/231/31
PyrexiaGeneral disorders5/1082/1081/1111/672/793/2958/4401/1711/1296/2037/1979/1994/1228/1251/751/231/31

Baseline characteristics

Full analysis set (FAS) which included all randomized participants (in IS-1 and IS-2) with a modified Mayo score (MMS) of 5 to 9 who received at least 1 (partial or complete) dose of study intervention.

Age, Continuous
Age, Continuous(Years)IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8Total
Mean41.2 ± 15.0543.3 ± 14.2840.4 ± 13.8439.8 ± 13.4341 ± 13.940.9 ± 13.93
Sex: Female, Male
Sex: Female, Male(Participants)IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8Total
Female394148119183430
Male666059161238584
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8Total
Hispanic or Latino454212559
Not Hispanic or Latino979298240368895
Unknown or Not Reported445192860
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8Total
American Indian or Alaska Native000011
Asian2423276288224
Native Hawaiian or Other Pacific Islander000011
Black or African American1113410
White777374205304733
More than one race010012
Unknown or Not Reported335102243
Region of Enrollment
Region of Enrollment(Participants)IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8Total
Argentina00251017
Australia21271426
Belgium100337
Brazil020121529
Bulgaria101237
Canada000257
China722263572
Czech Republic121111732
France5106103061
Germany33311828
Hungary453111740
Ireland000101
Israel0115714
Italy526141542
Japan91215253394
Jordan000161834
Latvia000538
Malaysia000347
New Zealand001258
Poland1922244771183
Portugal221106
Russian Federation976182060
Serbia0005510
Slovakia00021214
South Korea67521131
Spain211228
Sweden210036
Taiwan213219
Turkey00231116
Ukraine161614132079
United Kingdom3113614
United States637111744
08

Study locations

392 sites

Showing the first 100 of 392 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lichtenstein GR, Allegretti JR, Rubin DT, Magro F, Bressler B, Panes J, Afif W, Samaan MA, Ye BD, Yarandi S, Germinaro M, Shipitofsky N, Miao Y, Zhang H, Dignass A, Sands BE, Hisamatsu T, Peyrin-Biroulet L. Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. Am J Gastroenterol. 2026 May 1. doi: 10.14309/ajg.0000000000004041. Online ahead of print. PubMed 42065421 ↗
  • Hart A, Sridhar S, Venkat S, Lee T, Rusbuldt JJ, Richards D, Sisk C, Horowitz D, Tomsho L, Kannan AK, Ruane D, Van den Berge K, Rubin DT, Sands BE, De Hertogh G, Huang KG, Germinaro M, Cua D, Waterworth D, Freeman TC, Vetter ML, McRae B, Verstockt B, Branigan P. Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis. BMJ Open Gastroenterol. 2026 Mar 23;13(1):e002153. doi: 10.1136/bmjgast-2025-002153. PubMed 41871904 ↗
  • Chen B, Ye BD, Cao Q, Hirai F, Saruta M, Chen M, Pelak S, Shipitofsky N, Miao Y, Herr K, Wahking B, Zhuo J, Hisamatsu T. Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies. J Gastroenterol Hepatol. 2025 Sep;40(9):2197-2208. doi: 10.1111/jgh.17036. Epub 2025 Jun 26. PubMed 40574492 ↗
  • Rubin DT, Allegretti JR, Panes J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. PubMed 39706209 ↗
  • Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panes J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. PubMed 37659673 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2023, 47 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2019
First posted
Jul 26, 2019
StartActual
Sep 26, 2019
Primary completionActual
Sep 19, 2023
CompletionEst.
Jul 16, 2027
Results first posted
Nov 18, 2024
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04033445
Responsible party
Sponsor
First posted
Jul 26, 2019
Start date
Sep 26, 2019
Primary completion
Sep 19, 2023
Completion
Jul 16, 2027 (estimated)
Results posted
Nov 18, 2024
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion